{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:10:24Z","timestamp":1790662224348,"version":"4.1.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T00:00:00Z","timestamp":1434412800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ZonMW","award":["836011009"],"award-info":[{"award-number":["836011009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13023-015-0296-8","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T05:23:45Z","timestamp":1434605025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Quality of life in patients with Fabry disease: a systematic review of the literature"],"prefix":"10.1186","volume":"10","author":[{"given":"Maarten","family":"Arends","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E. M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Biegstraaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,16]]},"reference":[{"key":"296_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249\u201354.","journal-title":"JAMA"},{"key":"296_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s004399900075","volume":"105","author":"BJ Poorthuis","year":"1999","unstructured":"Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105:151\u20136.","journal-title":"Hum Genet"},{"key":"296_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1023\/A:1015511908710","volume":"11","author":"KF Gold","year":"2002","unstructured":"Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W, et al. Quality of life of patients with Fabry disease. Qual Life Res. 2002;11:317\u201327.","journal-title":"Qual Life Res"},{"key":"296_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","volume":"379","author":"TP Mechtler","year":"2012","unstructured":"Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet. 2012;379:335\u201341.","journal-title":"Lancet"},{"key":"296_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31\u201340.","journal-title":"Am J Hum Genet"},{"key":"296_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L van der Tol","year":"2014","unstructured":"van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51:1\u20139.","journal-title":"J Med Genet"},{"key":"296_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38:769\u201375.","journal-title":"J Med Genet"},{"key":"296_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","volume":"84","author":"S Gupta","year":"2005","unstructured":"Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine. 2005;84:261\u20138.","journal-title":"Medicine"},{"key":"296_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93:112\u201328.","journal-title":"Mol Genet Metab"},{"key":"296_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.ajkd.2003.09.022","volume":"43","author":"SM Meehan","year":"2004","unstructured":"Meehan SM, Junsanto T, Rydel JJ, Desnick RJ. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications. Am J Kidney Diseases Off J National Kidney Foundation. 2004;43:164\u201371.","journal-title":"Am J Kidney Diseases Off J National Kidney Foundation"},{"key":"296_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1056\/NEJM199508033330504","volume":"333","author":"S Nakao","year":"1995","unstructured":"Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al. An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288\u201393.","journal-title":"N Engl J Med"},{"key":"296_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013;8:47.","journal-title":"Orphanet J Rare Dis"},{"key":"296_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/joim.12077","volume":"274","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Niemann M, Stork S, Breunig F, Beer M, Sommer C, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274:331\u201341.","journal-title":"J Intern Med"},{"key":"296_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10545-014-9677-8","volume":"37","author":"SM Rombach","year":"2014","unstructured":"Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: Effectiveness of ERT in different disease stages. J Inherit Metab Dis. 2014;37:341\u201352.","journal-title":"J Inherit Metab Dis"},{"key":"296_CR15","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin 3rd HA, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743\u20139.","journal-title":"JAMA"},{"key":"296_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","volume":"12","author":"T Watt","year":"2010","unstructured":"Watt T, Burlina AP, Cazzorla C, Schonfeld D, Banikazemi M, Hopkin RJ, et al. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med. 2010;12:703\u201312.","journal-title":"Genet Med"},{"key":"296_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1750-1172-7-74","volume":"7","author":"W Hughes-Wilson","year":"2012","unstructured":"Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74.","journal-title":"Orphanet J Rare Dis"},{"key":"296_CR18","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750\u201360.","journal-title":"J Med Genet"},{"key":"296_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1023\/A:1015009210639","volume":"11","author":"A Miners","year":"2002","unstructured":"Miners A, Holmes A, Sherr L, Jenkinson C, MacDermot K. Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention. Qual Life Res An Int J Qual Life Aspects Treatment, Care Rehabilitation. 2002;11:127\u201333.","journal-title":"Qual Life Res An Int J Qual Life Aspects Treatment, Care Rehabilitation"},{"key":"296_CR20","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1542\/peds.2004-1678","volume":"115","author":"M Ries","year":"2005","unstructured":"Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, et al. Pediatric Fabry disease. Pediatrics. 2005;115:e344\u201355.","journal-title":"Pediatrics"},{"key":"296_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1477-7525-10-116","volume":"10","author":"U Ramaswami","year":"2012","unstructured":"Ramaswami U, Stull DE, Parini R, Pintos-Morell G, Whybra C, Kalkum G, et al. Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ). Health Qual Life Outcomes. 2012;10:116.","journal-title":"Health Qual Life Outcomes"},{"key":"296_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16390","volume":"16","author":"K Wyatt","year":"2012","unstructured":"Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess. 2012;16:1\u2013543.","journal-title":"Health Technol Assess"},{"key":"296_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/01.gim.0000223545.63012.5a","volume":"8","author":"NJ Street","year":"2006","unstructured":"Street NJ, Yi MS, Bailey LA, Hopkin RJ. Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease. Genet Med. 2006;8:346\u201353.","journal-title":"Genet Med"},{"key":"296_CR24","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1136\/jnnp.2008.143693","volume":"79","author":"S Buechner","year":"2008","unstructured":"Buechner S, Moretti M, Burlina A, Cei G, Manara R, Ricci R, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry. 2008;79:1249\u201354.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"296_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ymgme.2012.02.008","volume":"106","author":"C Cazzorla","year":"2012","unstructured":"Cazzorla C, Del Rizzo M, Burgard P, Zanco C, Bordugo A, Burlina AB, et al. Application of the WHOQOL-100 for the assessment of quality of life of adult patients with inherited metabolic diseases. Mol Genet Metab. 2012;106:25\u201330.","journal-title":"Mol Genet Metab"},{"key":"296_CR26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10545-011-9447-9","volume":"35","author":"MG Bouwman","year":"2012","unstructured":"Bouwman MG, Rombach SM, Schenk E, Sweeb A, Wijburg FA, Hollak CE, et al. Prevalence of symptoms in female Fabry disease patients: a case\u2013control survey. J Inherit Metab Dis. 2012;35:891\u20138.","journal-title":"J Inherit Metab Dis"},{"key":"296_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","volume":"15","author":"A Milligan","year":"2006","unstructured":"Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs. 2006;15:330\u20133.","journal-title":"Br J Nurs"},{"key":"296_CR28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1155\/2006\/828964","volume":"11","author":"AL Gibas","year":"2006","unstructured":"Gibas AL, Klatt R, Johnson J, Clarke JTR, Katz J. A survey of the pain experienced by males and females with Fabry disease. Pain Res Manag. 2006;11:185\u201392.","journal-title":"Pain Res Manag"},{"key":"296_CR29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.optm.2010.02.011","volume":"81","author":"AM Morier","year":"2010","unstructured":"Morier AM, Minteer J, Tyszko R, McCann R, Clarke MV, Browning MF. Ocular manifestations of Fabry disease within in a single kindred. Optometry (St Louis, Mo). 2010;81:437\u201349.","journal-title":"Optometry (St Louis, Mo)"},{"key":"296_CR30","first-page":"473","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I Conceptual Framework Item Selection Med Care. 1992;30:473\u201383.","journal-title":"I Conceptual Framework Item Selection Med Care"},{"key":"296_CR31","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jama.1989.03430070055030","volume":"262","author":"AL Stewart","year":"1989","unstructured":"Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD, et al. Functional status and well-being of patients with chronic conditions. Results from the medical outcomes study. JAMA. 1989;262:907\u201313.","journal-title":"JAMA"},{"key":"296_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hec.4730020305","volume":"2","author":"RD Hays","year":"1993","unstructured":"Hays RD, Sherbourne CD, The MRM, RAND. 36-item health survey 1.0. Health Econ. 1993;2:217\u201327.","journal-title":"Health Econ"},{"key":"296_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol-Group","year":"1990","unstructured":"EuroQol-Group. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"296_CR34","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s11136-004-7713-0","volume":"14","author":"SJ Walters","year":"2005","unstructured":"Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res Int J Qual Life Aspects Treatment, Care Rehabilitation. 2005;14:1523\u201332.","journal-title":"Qual Life Res Int J Qual Life Aspects Treatment, Care Rehabilitation"},{"key":"296_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.","journal-title":"Health Qual Life Outcomes"},{"key":"296_CR36","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap. 1994;23:129\u201338.","journal-title":"Ann Acad Med Singap"},{"key":"296_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain Off J Am Pain Soc. 2008;9:105\u201321.","journal-title":"J Pain Off J Am Pain Soc"},{"key":"296_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","volume":"26","author":"F Baehner","year":"2003","unstructured":"Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis. 2003;26:617\u201327.","journal-title":"J Inherit Metab Dis"},{"key":"296_CR39","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.clinthera.2012.03.033","volume":"34","author":"T Duning","year":"2012","unstructured":"Duning T, Stypmann J, Schaefer R, Young P. Excessive daytime sleepiness is a common symptom in fabry disease. Clin Therapeutics. 2012;34:e19.","journal-title":"Clin Therapeutics."},{"key":"296_CR40","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1445-5994.2007.01366.x","volume":"37","author":"M Low","year":"2007","unstructured":"Low M, Nicholls K, Tubridy N, Hand P, Velakoulis D, Kiers L, et al. Neurology of Fabry disease. Internal Med J. 2007;37:436\u201347.","journal-title":"Internal Med J"},{"key":"296_CR41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/8904_2012_136","volume":"7","author":"FL Oliveira","year":"2013","unstructured":"Oliveira FL, Alegra T, Dornelles A, Krug B, Netto CBO, da Rocha NS, et al. Quality of life of brazilian patients with Gaucher disease and fabry disease. Jimd Reports. 2013;7:31\u20137.","journal-title":"Jimd Reports"},{"key":"296_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1750-1172-6-69","volume":"6","author":"BE Smid","year":"2011","unstructured":"Smid BE, Rombach SM, Aerts JM, Kuiper S, Mirzaian M, Overkleeft HS, et al. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis. 2011;6:69.","journal-title":"Orphanet J Rare Dis"},{"key":"296_CR43","first-page":"34","volume":"9","author":"RY Wang","year":"2007","unstructured":"Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med Off J Am College Med Genet. 2007;9:34\u201345.","journal-title":"Genet Med Off J Am College Med Genet"},{"key":"296_CR44","first-page":"741","volume":"6","author":"W Zuraw","year":"2011","unstructured":"Zuraw W, Golicki D, Jurecka A, Tylki-Szymanska A. Quality of life among polish Fabry patients\u2013a cross-sectional study quality of life among polish fabry patients. Central European J Med. 2011;6:741\u20139.","journal-title":"Central European J Med"},{"key":"296_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1136\/jech.53.1.46","volume":"53","author":"C Jenkinson","year":"1999","unstructured":"Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health. 1999;53:46\u201350.","journal-title":"J Epidemiol Community Health"},{"key":"296_CR46","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1468-1331.2010.03155.x","volume":"18","author":"I Schermuly","year":"2011","unstructured":"Schermuly I, Muller M, Muller K, Albrecht J, Keller I, Yakushev I, et al. Neuropsychiatric symptoms and brain structural alterations in Fabry disease. Eur J Neurol. 2011;18:347\u201353.","journal-title":"Eur J Neurol"},{"issue":"6","key":"296_CR47","first-page":"658","volume":"13","author":"H Quinn","year":"2010","unstructured":"Quinn H, Tchan MC, Sillence DO. Quality of life and MRI changes in hemizygote male and heterozygote female patients with fabry disease. Twin Res Human Genet. 2010;13(6):658.","journal-title":"Twin Res Human Genet"},{"key":"296_CR48","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1210\/jc.2006-0858","volume":"91","author":"A Faggiano","year":"2006","unstructured":"Faggiano A, Pisani A, Milone F, Gaccione M, Filippella M, Santoro A, et al. Endocrine dysfunction in patients with Fabry disease. J Clin Endocrinol Metabolism. 2006;91:4319\u201325.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"296_CR49","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.pain.2009.06.032","volume":"145","author":"A Torvin Moller","year":"2009","unstructured":"Torvin Moller A, Winther Bach F, Feldt-Rasmussen U, Rasmussen A, Hasholt L, Lan H, et al. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease. Pain. 2009;145:237\u201345.","journal-title":"Pain"},{"key":"296_CR50","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","volume":"30","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, Linthorst GE, van Breemen MJ, Groener JEM, Bemelman FJ, Strijland A, et al. The dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis. 2007;30:68\u201378.","journal-title":"J Inherit Metab Dis"},{"key":"296_CR51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004;75:65\u201374.","journal-title":"Am J Hum Genet"},{"key":"296_CR52","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ymgme.2011.07.006","volume":"104","author":"MG Bouwman","year":"2011","unstructured":"Bouwman MG, Maurice-Stam H, Linthorst GE, Hollak CEM, Wijburg FA, Grootenhuis MA. Impact of growing up with Fabry disease on achievement of psychosocial milestones and quality of life. Molecular Genet Metabolism. 2011;104:308\u201313.","journal-title":"Molecular Genet Metabolism"},{"key":"296_CR53","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/jmg.2004.025791","volume":"42","author":"B Hoffmann","year":"2005","unstructured":"Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R, et al. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet. 2005;42:247\u201352.","journal-title":"J Med Genet"},{"key":"296_CR54","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","volume":"374","author":"A Mehta","year":"2009","unstructured":"Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data. Lancet. 2009;374:1986\u201396.","journal-title":"Lancet"},{"key":"296_CR55","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/jmg.2005.036327","volume":"43","author":"PB Deegan","year":"2006","unstructured":"Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M, et al. Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet. 2006;43:347\u201352.","journal-title":"J Med Genet"},{"key":"296_CR56","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1529-8027.2012.00438.x","volume":"17","author":"N Geevasinga","year":"2012","unstructured":"Geevasinga N, Tchan M, Sillence D, Vucic S. Upregulation of inward rectifying currents and Fabry disease neuropathy. J Peripher Nerv Syst. 2012;17:399\u2013406.","journal-title":"J Peripher Nerv Syst"},{"key":"296_CR57","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/j.1742-1241.2011.02695.x","volume":"65","author":"MA Barba-Romero","year":"2011","unstructured":"Barba-Romero MA, Rivera-Gallego A, Pintos-Morell G. Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry outcome survey (FOS). Int J Clin Pract. 2011;65:903\u201310.","journal-title":"Int J Clin Pract"},{"key":"296_CR58","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/1471-2369-15-188","volume":"15","author":"M Wagner","year":"2014","unstructured":"Wagner M, Kramer J, Blohm E, Vergho D, Weidemann F, Breunig F, et al. Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease. BMC Nephrol. 2014;15:188.","journal-title":"BMC Nephrol"},{"key":"296_CR59","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1750-1172-8-29","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Hollak CE, Linthorst GE, Dijkgraaf MG. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J Rare Dis. 2013;8:29.","journal-title":"Orphanet J Rare Dis"},{"key":"296_CR60","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","volume":"5","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Schwarz M, Mehta A, Keshav S. Fabry outcome survey European I. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol. 2007;5:1447\u201353.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"296_CR61","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.clinthera.2012.03.038","volume":"1","author":"I Kantola","year":"2012","unstructured":"Kantola I, Hietaharju A, Taurio J, Kananen K, Kantola T, Viikari J. Quality of life did not worsen for 7\u00a0years in enzyme-replacement therapy recipients with fabry disease. Clin Ther. 2012;1:e21\u20132.","journal-title":"Clin Ther"},{"key":"296_CR62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A\u2013replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001;345:9\u201316.","journal-title":"N Engl J Med"},{"key":"296_CR63","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"CM Eng","year":"2001","unstructured":"Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, et al. A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet. 2001;68:711\u201322.","journal-title":"Am J Hum Genet"},{"key":"296_CR64","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10545-005-0575-y","volume":"28","author":"Y Eto","year":"2005","unstructured":"Eto Y, Ohashi T, Utsunomiya Y, Fujiwara M, Mizuno A, Inui K, et al. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis. 2005;28:575\u201383.","journal-title":"J Inherit Metab Dis"},{"key":"296_CR65","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54\u00a0months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18:1547\u201357.","journal-title":"J Am Soc Nephrol"},{"key":"296_CR66","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s10545-008-0848-3","volume":"31","author":"JW Koskenvuo","year":"2008","unstructured":"Koskenvuo JW, Hartiala JJ, Nuutila P, Kalliokoski R, Viikari JS, Engblom E, et al. Twenty-four-month alpha-galactosidase a replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab Dis. 2008;31:432\u201341.","journal-title":"J Inherit Metab Dis"},{"key":"296_CR67","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","volume":"103","author":"DA Hughes","year":"2011","unstructured":"Hughes DA, Barba Romero MA, Hollak CEM, Giugliani R, Deegan PB. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS-the Fabry outcome survey. Mol Genet Metab. 2011;103:207\u201314.","journal-title":"Mol Genet Metab"},{"key":"296_CR68","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ymgme.2013.04.015","volume":"109","author":"DA Hughes","year":"2013","unstructured":"Hughes DA, Deegan PB, Milligan A, Wright N, Butler LH, Jacobs A, et al. A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease. Mol Genet Metab. 2013;109:269\u201375.","journal-title":"Mol Genet Metab"},{"key":"296_CR69","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1055\/s-0033-1349624","volume":"138","author":"M Beck","year":"2013","unstructured":"Beck M, Gaedeke J, Martus P, Karabul N, Rolfs A. Home-based infusion therapy\u2013a feasible approach for chronically ill patients? a new path to provide superior patient care exemplified for Fabry\u2019s disease. [German]. Dtsch Med Wochenschr. 2013;138:2345\u201350.","journal-title":"Dtsch Med Wochenschr"},{"key":"296_CR70","volume-title":"European Medicines Agency","author":"Assessment report on the shortage of Fabrazyme (EMEA\/H\/C\/000370)","year":"2010","unstructured":"Assessment report on the shortage of Fabrazyme (EMEA\/H\/C\/000370). European Medicines Agency. 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2010\/11\/WC500099241.pdf. Accessed 02-03-2015."},{"key":"296_CR71","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/8904_2011_44","volume":"3","author":"J Ghali","year":"2012","unstructured":"Ghali J, Nicholls K, Denaro C, Sillence D, Chapman I, Goldblatt J, et al. Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience. Jimd Reports. 2012;3:33\u201343.","journal-title":"Jimd Reports"},{"key":"296_CR72","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/gim.2012.39","volume":"14","author":"K Tsuboi","year":"2012","unstructured":"Tsuboi K, Yamamoto H. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). Genet Med. 2012;14:779\u201386.","journal-title":"Genet Med"},{"key":"296_CR73","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","volume":"96","author":"U Ramaswami","year":"2007","unstructured":"Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr. 2007;96:122\u20137.","journal-title":"Acta Paediatr"},{"key":"296_CR74","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res. 2008;64:550\u20135.","journal-title":"Pediatr Res"},{"key":"296_CR75","doi-asserted-by":"publisher","first-page":"524894","DOI":"10.1155\/2013\/524894","volume":"2013","author":"K Baumstarck","year":"2013","unstructured":"Baumstarck K, Boyer L, Boucekine M, Michel P, Pelletier J, Auquier P. Measuring the quality of life in patients with multiple sclerosis in clinical practice: a necessary challenge. Multiple Sclerosis Int. 2013;2013:524894.","journal-title":"Multiple Sclerosis Int"},{"key":"296_CR76","doi-asserted-by":"publisher","first-page":"S217","DOI":"10.1097\/00005650-198903001-00018","volume":"27","author":"DL Patrick","year":"1989","unstructured":"Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27:S217\u201332.","journal-title":"Med Care"},{"key":"296_CR77","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-6-16","volume":"6","author":"CE Hollak","year":"2011","unstructured":"Hollak CE, Aerts JM, Ayme S, Manuel J. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Diseases. 2011;6:16.","journal-title":"Orphanet J Rare Diseases"},{"key":"296_CR78","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1475-6773.2005.0l374.x","volume":"40","author":"KW Wyrwich","year":"2005","unstructured":"Wyrwich KW, Tierney WM, Babu AN, Kroenke K, Wolinsky FD. A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv Res. 2005;40:577\u201391.","journal-title":"Health Serv Res"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-015-0296-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0296-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T16:22:11Z","timestamp":1630599731000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-015-0296-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,16]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["296"],"URL":"https:\/\/doi.org\/10.1186\/s13023-015-0296-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,16]]},"assertion":[{"value":"14 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"77"}}